<code id='FA94578BC0'></code><style id='FA94578BC0'></style>
    • <acronym id='FA94578BC0'></acronym>
      <center id='FA94578BC0'><center id='FA94578BC0'><tfoot id='FA94578BC0'></tfoot></center><abbr id='FA94578BC0'><dir id='FA94578BC0'><tfoot id='FA94578BC0'></tfoot><noframes id='FA94578BC0'>

    • <optgroup id='FA94578BC0'><strike id='FA94578BC0'><sup id='FA94578BC0'></sup></strike><code id='FA94578BC0'></code></optgroup>
        1. <b id='FA94578BC0'><label id='FA94578BC0'><select id='FA94578BC0'><dt id='FA94578BC0'><span id='FA94578BC0'></span></dt></select></label></b><u id='FA94578BC0'></u>
          <i id='FA94578BC0'><strike id='FA94578BC0'><tt id='FA94578BC0'><pre id='FA94578BC0'></pre></tt></strike></i>

          Home / explore / leisure time

          leisure time


          leisure time

          author:Wikipedia    Page View:3
          Adam's take main illustration
          Molly Ferguson/STAT

          Biotech is awash in PIPEs.

          The numbers behind these privately negotiated purchases of public-company stock are astounding. By my count, there have been 30 PIPE transactions involving public biotechs and institutional investors (mostly hedge funds) that have raised $4 billion in the first two months of the year.

          advertisement

          Just this week, five biotechs have brought in a combined $950 million via PIPEs, including Denali Therapeutics raising $500 million, the largest such financing this year. Crinetics Pharmaceuticals raised $350 million.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In